Analytical Data
-
Gene name
HLA-A*02:01&B2M&HPV16 E6(KLPQLCTEL) Tetramer
- Application
-
Alternative Names
rHuHLA-A*0201 HPV16 E6 complex Protein
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A140T913 (G25-T305)&P61769
-
Expression Region
A0A140T913 (G25-T305)&P61769 (I21-M119)&KLPQLCTEL
-
Molecular Weight
260-265 kDa under Non reducing (N)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/HPV16 E6 (KLPQLCTEL) tetramer recombinant protein is pivotal in understanding immune responses against human papillomavirus (HPV) infection, which is closely associated with the development of cervical cancer. The HLA-A*02:01 allele is one of the most prevalent human leukocyte antigen molecules, playing a crucial role in presenting viral peptides to CD8+ T cells, thereby initiating a cytotoxic T cell response. The E6 protein of HPV16 is a key oncogenic factor that interferes with host cellular mechanisms, and the specific peptide KLPQLCTEL is recognized by T cells in HLA-A*02:01 restricted pathways. The development of tetrameric complexes that consist of HLA-A*02:01, β2-microglobulin (B2M), and the HPV16 E6 peptide allows for the direct visualization and quantification of HPV E6-specific T cells in peripheral blood. This approach enhances our understanding of the immune landscape in HPV-associated malignancies and aids in the evaluation of immunotherapeutic strategies. By leveraging tetramer technology, researchers can analyze T cell responses, monitor vaccine efficacy, and explore the potential for personalized immunotherapies against HPV-induced cancers. This research ultimately contributes to the advancement of effective prevention and treatment strategies for HPV-related diseases, aiming to reduce cervical cancer incidence globally.
